COMMUNIQUÉS West-GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
MIMEDX to Participate in Upcoming Investor Conferences
06/11/2026
MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
06/11/2026
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026 BOND-003 Cohort P and CORE-008 Cohort CX 12-month data [...]
Notification of managers’ transactions
06/11/2026
ANNOUNCEMENT NO. 327 6 November 2026 ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation No. 596/2014 concerning transactions in shares of ChemoMetec A/S carried out by persons [...]
OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook
06/11/2026
MINNEAPOLIS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI [...]
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
06/11/2026
SUNNYVALE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ: BCDA) , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
06/11/2026
Kristi and Kodi Share Their Experience Living with the Rare Genetic Skin Disease, Alongside Insights from Pediatric Dermatologist Moise Levy, MD Kodi, who lives with Netherton Syndrome, in the latest NETHERTON NOW [...]
CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
06/11/2026
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens [...]
ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London
06/11/2026
SAN CLEMENTE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will [...]
Azalea Therapeutics Presents New Preclinical Data at SITC 2026 Highlighting Durable Anti-Tumor Activity and Modular Capabilities of its In Vivo CAR T Cell Platform
06/11/2026
In vivo-engineered TRAC-CAR T cells demonstrate complete leukemia tumor clearance in mice, including following tumor rechallenge without additional dosing Modular platform enables dual-antigen targeting to limit tumor [...]
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
06/11/2026
- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival extended by 1.8- [...]
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
06/11/2026
Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (NSCLC), and for [...]
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
06/11/2026
CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent [...]
SOTIO Presents Initial Data from VICTORIA-01 Phase 1 Clinical Study of Immunocytokine SOT201 at SITC Annual Meeting
06/11/2026
SOT201, a novel cis-acting immunocytokine, combines IL-15 superagonist and anti-PD-1 activity in order to stimulate tumor specific T cells Data show early evidence of durable antitumor activity with SOT201, including [...]
Immunocore reports third quarter financial results and provides a business update
06/11/2026
KIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for [...]
Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
06/11/2026
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and [...]
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
06/11/2026
Bria-OTS+™ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor models BriaPro data highlights BP-80 tolerability in primates and advances in tumor-targeted checkpoint inhibition [...]
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
06/11/2026
Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma Findings provide an immunological mechanism for [...]
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
06/11/2026
Colorectal cance r: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing, reinforcing the rationale [...]

Pages